(Q36269613)

13 August 2017

1 reference

title

Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins (English)

1 reference

13 August 2017

1 reference

1 reference

1 reference

David Ternant

1

1 reference

13 August 2017

Gilles Paintaud

series ordinal

2

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 September 2005

1 reference

Expert Opinion on Biological Therapy

13 August 2017

published in

1 reference

13 August 2017

volume

5 Suppl 1

1 reference

13 August 2017

page(s)

S37-47

1 reference

Continuous cultures of fused cells secreting antibody of predefined specificity

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S37

Anti-immunoglobulin E therapy for asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S37

Pharmacokinetics, biologic activity, and tolerability of alefacept by intravenous and intramuscular administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S37

Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S37

Rituximab: perspective on single agent experience, and future directions in combination trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S37

A review of modifications to recombinant antibodies: attempt to increase efficacy in oncology applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S37

Tumour-targeted chemotherapy with immunoconjugates of calicheamicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S37

Metabolic properties of IgG subclasses in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S37

The MHC class I-related receptor, FcRn, plays an essential role in the maternofetal transfer of gamma-globulin in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S37

FcRn: the MHC class I-related receptor that is more than an IgG transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S37

The stoichiometry and affinity of the interaction of murine Fc fragments with the MHC class I-related receptor, FcRn

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S37

Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S37

Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S37

Comparative Pharmacology of GP IIb/IIIa Antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S37

Engineered human IgG antibodies with longer serum half-lives in primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S37

Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S37

Population pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S37

A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S37

New drugs for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S37

Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S37

Simultaneous Modeling of Abciximab Plasma Concentrations and ex Vivo Pharmacodynamics in Patients Undergoing Coronary Angioplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S37

Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S37

IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S37

Rituximab: expanding role in therapy for lymphomas and autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S37

Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S37

Disposition and immunodynamics of basiliximab in liver allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S37

Constructing a prediction interval for time to reach a threshold concentration based on a population pharmacokinetic analysis: an application to basiliximab in renal transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S37

From the bench to the bedside: ways to improve rituximab efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S37

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S37

FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S37

FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S37

Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S37

The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S37

Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S37

A single recombinant anti-RhD IgG prevents RhD immunization: association of RhD-positive red blood cell clearance rate with polymorphisms in the FcgammaRIIA and FcgammaIIIA genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S37

Abciximab pharmacodynamic model with neural networks used to integrate sources of patient variability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S37

Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S37

Omalizumab: a review of its use in the management of allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.S37

21 January 2018

Identifiers

DOI

10.1517/14712598.5.1.S37

1 reference

13 August 2017

1 reference